Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).

Autor:	Maluf FC; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Beneficência Portuguesa de São Paulo, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil., Pereira FMT; Latin American Oncology Group (LACOG), Porto Alegre, Brazil., Silva AG; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Oncologia Clínica ICTr, Curitiba, Brazil., Dettino ALA; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Hospital AC Camargo, São Paulo, Brazil., Cardoso APG; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil., Sasse AS; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Grupo Sonhe, Campinas, Brazil., Soares A; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Centro Paulista de Oncologia, Oncoclínicas, São Paulo, Brazil., Kann AG; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Herchenhorn D; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Grupo de oncologia D'Or, Rio de Janeiro, Brazil.; Instituto D'Or de ensino e pesquisa, Rio de Janeiro, Brazil., Jardim DLF; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Hospital Sírio Libanês, São Paulo, Brazil., Cortés DEL; Clínica Oncólogos del Occidente SAS, Manizales, Colombia., Kater FR; Beneficência Portuguesa de São Paulo, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil., Morbeck IAP; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Hospital Sírio Libanês, Brasília, Brazil.; Universidade Católica de Brasília, Brasília, Brazil., Reolon JFN; Beneficência Portuguesa de São Paulo, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil., Rinck JA Jr; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Hospital AC Camargo, São Paulo, Brazil., Zarbá JJ; Hospital Zenon Santillán, Nacional University of Tucumán, Tucumán, Argentina., Sade JP; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Instituto Alexander Fleming y de la Universidad Austral, Buenos Aires, Argentina., da Trindade KM; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; IEP-Instituto de Ensino e Pesquisa Oncocentro, Fortaleza, Brazil., Costa LAGA; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Grupo de oncologia D'Or, Rio de Janeiro, Brazil., Dos Santos LV; Beneficência Portuguesa de São Paulo, São Paulo, Brazil., Maia MC; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Centro de Oncologia do Paraná, Curitiba, Brazil., Siqueira MB; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Grupo de oncologia D'Or, Rio de Janeiro, Brazil., Gillessen S; Oncology Institute of Southern Switzerland (IOSI), Bellinzona and Università della Svizzera Italiana, Lugano, Switzerland.; Manchester Cancer Research Centre, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.
Jazyk:	angličtina
Zdroj:	JCO global oncology [JCO Glob Oncol] 2021 Apr; Vol. 7, pp. 559-571.
DOI:	10.1200/GO.20.00511
Abstrakt:	Purpose: To present a summary of the recommendations for the treatment and follow-up for metastatic castration-resistant prostate cancer (mCRPC) as acquired through a questionnaire administered to 99 physicians working in the field of prostate cancer in developing countries who attended the Prostate Cancer Consensus Conference for Developing Countries. Methods: A total of 106 questions out of more than 300 questions addressed the use of imaging in staging mCRPC, treatment recommendations across availability and response to prior drug treatments, appropriate drug treatments, and follow-up, and those same scenarios when limited resources needed to be considered. Responses were compiled and the percentages were presented by clinicians to support each response. Most questions had five to seven relevant options for response including abstain and/or unqualified to answer, or in the case of yes or no questions, the option to abstain was offered. Results: Most of the recommendations from this panel were in line with prior consensus, including the preference of a new antiandrogen for first-line therapy of mCRPC. Important aspects highlighted in the scenario of limited resources included the option of docetaxel as treatment preference as first-line treatment in several scenarios, docetaxel retreatment, consideration for reduced doses of abiraterone, and alternative schedules of an osteoclast-targeted therapy. Conclusion: There was wide-ranging consensus in the treatment for men with mCRPC in both optimal and limited resource settings. Competing Interests: Fernando Cotait MalufHonoraria: Janssen Oncology, Astellas Pharma, Bayer Schering Pharma, Merck Sharp & Dohme, Roche/Genentech, BMS Brazil, Ipsen, Sanofi/Aventis, Merck Serono, AstraZenecaConsulting or Advisory Role: Janssen Oncology, Astellas Pharma, Bayer Schering Pharma, Merck Sharp & Dohme, Roche/Genentech, BMS Brazil, Ipsen, Merck Serono, AstraZenecaResearch Funding: Janssen-Cilag, Merck Sharp & DohmeTravel, Accommodations, Expenses: Merck Sharp & Dohme, Bayer Schering Pharma Felipe MoraesHonoraria: Janssen, Zodiac Pharma, MSD, Libbs, Bayer, AmgenConsulting or Advisory Role: Janssen Adriano Gonçalves SilvaHonoraria: MSD Oncology, Janssen Oncology, Astellas Pharma, Roche, Pfizer/EMD Serono, Bayer, BMS BrazilConsulting or Advisory Role: Janssen Oncology, Astellas Pharma, Pfizer/EMD Serono, MSD OncologyResearch Funding: MSD Oncology, Janssen OncologyTravel, Accommodations, Expenses: Janssen Oncology, Astellas Pharma, MSD Oncology, Roche Aldo Lourenço Abbade DettinoHonoraria: Janssen-Cilag, Bayer, Astellas Pharma, RocheConsulting or Advisory Role: NovartisResearch Funding: Janssen, RocheTravel, Accommodations, Expenses: MSD Oncology Ana Paula Garcia CardosoConsulting or Advisory Role: Janssen Oncology, Pfizer, Astellas PharmaSpeakers' Bureau: Janssen Oncology, Novartis, MSD Oncology, Astellas Pharma, AstraZeneca, BayerTravel, Accommodations, Expenses: Ipsen, Janssen Oncology, Bristol-Myers Squibb André Seeke SasseHonoraria: Roche, Astellas Pharma, Janssen-Cilag, Bristol-Myers Squibb, Merck KGaA, MSD Oncology, NovartisConsulting or Advisory Role: Astellas Pharma, Janssen-Cilag, Merck KGaA, Novartis, RocheResearch Funding: Bristol-Myers SquibbTravel, Accommodations, Expenses: MSD Oncology, Janssen-Cilag Andrey SoaresHonoraria: Janssen, Pfizer, Bayer, Novartis, AstraZeneca, Astellas Pharma, Pierre Fabre, Merck Serono, Sanofi, Roche, MSDConsulting or Advisory Role: Astellas Pharma, Janssen, Roche, Bayer, Lilly, AstraZeneca, Novartis, MSD, Bristol-Myers SquibbResearch Funding: Bristol-Myers SquibbTravel, Accommodations, Expenses: AstraZeneca, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Bayer, Roche, Janssen, Merck Serono, Sanofi, Ipsen, MSD Ariel Galapo KannConsulting or Advisory Role: Janssen OncologySpeakers' Bureau: Janssen Oncology, GlaxoSmithKline, Roche Daniel HerchenhornConsulting or Advisory Role: Janssen-Cilag Denis Leonardo Fontes JardimHonoraria: Janssen-Cilag, Roche/Genentech, Astellas Pharma, MSD Oncology, BMS Brazil, Pfizer, Libbs, MerckConsulting or Advisory Role: Janssen-Cilag, Pfizer, MSDTravel, Accommodations, Expenses: MSD, BMS Brazil, Janssen-Cilag Diego Emilio Lopera CortésConsulting or Advisory Role: Bristol-Myers Squibb, Pfizer, NovartisSpeakers' Bureau: Dr Reddy's Laboratories, Bristol-Myers Squibb, Boehringer Ingelheim, PfizerTravel, Accommodations, Expenses: MSD Oncology Fábio Roberto KaterConsulting or Advisory Role: Janssen-Cilag, PfizerTravel, Accommodations, Expenses: Janssen-Cilag Igor A. Protzner MorbeckHonoraria: Janssen-Cilag, BMS Brazil, AstraZeneca, MSD Oncology, Astellas PharmaConsulting or Advisory Role: BMS Brazil, Janssen-Cilag, TakedaTravel, Accommodations, Expenses: Astellas Pharma, BMS Brazil Juan Jose ZarbáConsulting or Advisory Role: Pfizer/EMD Serono, Astellas PharmaResearch Funding: MSD Oncology, Lilly, Exelixis, Astellas PharmaExpert Testimony: LillyTravel, Accommodations, Expenses: Roche, Pfizer Karine Martins da TrindadeHonoraria: BMS Brazil, Janssen-Cilag, MSD OncologyConsulting or Advisory Role: MSD Oncology, Janssen-Cilag, Astellas PharmaResearch Funding: BMS Brazil, Roche/Genentech, MSD Oncology, Janssen-CilagTravel, Accommodations, Expenses: Janssen-Cilag, BMS Brazil, Ipsen Leonardo Atem G. A. CostaHonoraria: Janssen Oncology, Astellas Pharma, AstraZenecaConsulting or Advisory Role: Janssen Oncology, Astellas Pharma, AstraZenecaTravel, Accommodations, Expenses: Janssen Oncology, Boehringer Ingelheim, Astellas Pharma, AstraZeneca Lucas V. dos SantosStock and Other Ownership Interests: Merck Sharp & Dohme, Eisai, Fleury GroupHonoraria: BMS Brazil, United Medical, Roche/GenentechConsulting or Advisory Role: Lilly, Bristol-Myers Squibb, MSD, Roche/GenentechSpeakers' Bureau: BMS Brazil, United MedicalResearch Funding: Roche/Genentech, Janssen Oncology, Novartis, GlaxoSmithKline, Amgen, Boston Scientific, Takeda, BMS Brazil, MSD, Exelixis Manuel Caitano MaiaConsulting or Advisory Role: AstraZeneca, Janssen OncologySpeakers' Bureau: Janssen Oncology, AstraZeneca, Bayer, MSD Oncology, Pfizer, Astellas PharmaExpert Testimony: MSD OncologyTravel, Accommodations, Expenses: Astellas Pharma, Janssen Oncology Mariana Bruno SiqueiraConsulting or Advisory Role: Novartis, Janssen-CilagSpeakers' Bureau: Novartis, MSD Oncology, Bayer, Janssen-CilagTravel, Accommodations, Expenses: Roche, Pfizer, Ipsen Silke GillessenConsulting or Advisory Role: Astellas Pharma, Advanced Accelerator Applications, Roche, Janssen, Bayer, Orion Pharma GmbH, Menarini Silicon Biosystems, Tolero Pharmaceuticals, MSD Oncology, Amgen, PfizerSpeakers' Bureau: Janssen-CilagPatents, Royalties, Other Intellectual Property: Method for biomarker (WO 3752009138392 A1)Travel, Accommodations, Expenses: ProteoMedixOther Relationship: ProteoMediX, Aranda PharmaNo other potential conflicts of interest were reported.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu